Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ptc Therapeutics (NQ: PTCT )

34.13 +0.71 (+2.12%)
Streaming Delayed Price Updated: 11:49 AM EDT, Aug 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ptc Therapeutics

< Previous 1 2 3 4 5 6 Next >
PTCT Stock Earnings: PTC Therapeutics Misses EPS, Beats Revenue for Q2 2024
PTCT stock results show that PTC Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
PTC Therapeutics Tumbles After European Regulators Reject Its Drug — Again
The company plans to ask for another re-examination for its drug in Europe. 
Via Investor's Business Daily
Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday
Via Benzinga
PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder
PTC Therapeutics released interim results from its Phase 2 PIVOT-HD study on PTC518 for Huntington's disease. The FDA has lifted the partial clinical hold on the program. 
Via Benzinga
Exposures Product Safety
Recap: PTC Therapeutics Q4 Earnings
Via Benzinga
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
Earnings Preview: PTC Therapeutics
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate 
Via InvestorPlace
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
European Commission Requests Reevaluation Of Opinion On PTC Therapeutics' Duchenne Dystrophy Drug; Pauses Annual Guidance
PTC Therapeutics announced that the European Commission has asked the CHMP to re-evaluate its negative opinion on the renewal of Translarna's conditional marketing authorization, keeping it available... 
Via Benzinga
Analyst Expectations for PTC Therapeutics's Future
Via Benzinga
Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
Via Benzinga
PTC Therapeutics Stock Soars As Its Biggest Drug 'Lives To Fight Another Day'
The EC is asking its committee to reexamine its decision on Translarna. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72. 
Via Investor's Business Daily
PTCT Stock Earnings: PTC Therapeutics Beats EPS, Beats Revenue for Q1 2024
PTCT stock results show that PTC Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?
Bad news for one player does not always equal good news for another. 
Via The Motley Fool
PTC Therapeutics Flashes A Bearish Sign After European Officials Reject DMD Drug
European regulators will likely force PTC Therapeutics to pull its drug, Translarna, from the market. 
Via Investor's Business Daily
PTC Therapeutics To Withdraw Its Conditionally Approved Rare Muscle Disorder Disorder Drug In Europe
CHMP issues negative opinion on PTC Therapeutics' Translarna for Duchenne Muscular Dystrophy. CEO expresses disappointment. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Is Gene Therapy Player PTC Therapeutics Stock Plunging Today?
In its Q3 earnings release, PTC Therapeutics Inc (NASDAQ: PTCT) reported a  
Via Benzinga
ALGN Stock Alert: Align Technology Announces $250M Stock Buyback Program
Align Technology stock is rising on Friday after the company announced plans to repurchase $250 million worth of ALGN shares. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
RBLX Stock Alert: Analysts Are Pounding the Table on Roblox
Roblox stock is rising higher on Friday after analysts upgraded shares of RBLX and increased price targets for the gaming company. 
Via InvestorPlace
Why Is PTC Therapeutics (PTCT) Stock Down 23% Today?
PTC Therapeutics stock is falling on Friday as PTCT investors react to the company's lackluster earnings report for Q3 2023. 
Via InvestorPlace
Amazon To Rally Around 55%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.